While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.

The doctor recommended getting updated flu vaccines annually to lower the risk of contracting the virus and be protected from ...

The new agreement comes at a time when GSK and CureVac have been at risk of falling behind in mRNA vaccines for respiratory diseases, with combined flu/COVID-19 candidates from Moderna and Pfizer ...

GSK said at an R&D update in the summer that it expects to have two mRNA candidates in clinical trials within 12 months and six within the next four years, including seasonal flu shots.

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Moderna, Pfizer, and a partnership between GSK and CureVac are reportedly working ... and Prevention reported the first death from bird flu on Monday, announcing an elderly patient with underlying ...

Bird flu has severely impacted poultry farms and ... Other players, including Pfizer and GSK (in collaboration with CureVac), are testing similar candidates. For investors who want to play the ...